about
Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signallingConstitutively active mutants of 5-HT4 receptors are they in unique active states?Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.Assignment of 5-hydroxytryptamine receptor (HTR4) to human chromosome 5 bands q31-->q33 by in situ hybridization.SAP97-mediated ADAM10 trafficking from Golgi outposts depends on PKC phosphorylation.Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors.5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling.Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation.Primary culture of mouse dopaminergic neurons.Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease.Phosphorylation of β-arrestin2 at Thr383 by MEK underlies β-arrestin-dependent activation of Erk1/2 by GPCRs.5-HT(4) receptors, a place in the sun: act two.Alzheimer culprits: cellular crossroads and interplay.A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists.Serotonin: A New Hope in Alzheimer's Disease?Uncoupling and endocytosis of 5-hydroxytryptamine 4 receptors. Distinct molecular events with different GRK2 requirements.Cerebrovascular pathology during the progression of experimental Alzheimer's disease.A conserved Asn in TM7 of the thyrotropin receptor is a common requirement for activation by both mutations and its natural agonist.Drosophila molting neurohormone bursicon is a heterodimer and the natural agonist of the orphan receptor DLGR2.5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10.A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL).Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease.5-HT4 receptors: cloning and expression of new splice variants.5-HT4 receptors: gene, transduction and effects on olfactory memory.Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases.Serotonin Type 4 Receptor DimersInhibition of glucose-induced insulin secretion by a peripheral-type benzodiazepine receptor ligand (PK11195)Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT4 receptors activities for the treatment of Alzheimer's diseaseA Novel in vivo Anti-amnesic Agent, Specially Designed to Express Both Acetylcholinesterase (AChE) Inhibitory, Serotonergic Subtype 4 Receptor (5-HT4R) Agonist and Serotonergic Subtype 6 Receptor (5-HT6R) Inverse Agonist Activities, With a PotentialDonecopride, a Swiss army knife with potential against Alzheimer's diseaseInhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's DiseaseNovel multi target-directed ligands targeting 5-HT4 receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease
P50
Q24321629-307FA43A-814A-4291-A91A-A7BAFC799C3BQ28360429-064C0E92-3ADB-40CF-82F9-E7355071A1DDQ33524509-D5028026-E959-464C-ACF5-09E0C09AC0DAQ34446563-54AF5EE0-6320-4593-B7D4-F35B56B9A012Q34662305-B1BD5BD8-C41B-43CF-8E9F-8EEC4D9F0AF8Q34929638-C86FB8CC-655B-46F4-8CA4-372ACD14CCEFQ35810546-56501205-35D0-4D9A-BA96-3AFB8E50E57BQ36560413-CD497CC2-5142-4896-A70A-F9F75C39ED7FQ36788096-999DF283-FFC6-4ADE-B9BC-5534AE8FE080Q37412086-7511BB68-BA12-41A8-9D07-43985275ED2FQ37665955-C68638A8-911E-4AF5-96B7-D62D2094AE44Q37845978-1BE55E34-492C-41D0-A044-3B4594D35FCBQ38012970-61CEF80A-057E-4494-8158-E309974CE091Q38289812-49867F40-0A4D-4B0C-982C-5D3699AAC456Q39188745-6856E801-AFE7-40E4-BEE1-840F494ADADBQ40416635-C758A0CA-B721-4BCC-9788-5DACD38A7167Q42487571-1E1B3764-CD98-47FA-91CF-04A554A57753Q42522311-B92E50A5-60DF-4A1E-BF2A-31A2BB21CE98Q42652628-BA6A2602-2176-4863-9E82-5EE2E44151F9Q42771475-FD5F9777-3B96-4ABD-A950-55599DC48B45Q44222512-5F9A8CD2-B96B-48C4-A9E1-463B83BC1DECQ46597819-3BEB710F-52D4-4DFD-845D-13D631DC8AC8Q47899938-BE80E22E-8015-41BB-9FB4-B671DDA8A0EFQ47990762-16EB5414-675A-4D24-9B65-93BF404E2004Q48294801-2F1C2B87-E1A3-4804-9D4C-098BC4648D65Q48369273-E8DB3F95-A49C-46E4-A46E-53BADC63511DQ62606348-A2646343-5744-4766-95A8-5299649354A4Q74144377-E7DF8293-0C3F-40F4-BCB3-C7A6F7DE7868Q89810688-E5447723-2245-4501-9F8A-21FAAA9F1732Q91970709-6D3B074C-7BC7-4BE6-84E8-64EEA1A15E1DQ92281391-E56A9EB7-AF10-4DAB-B8F2-0BAFB5CC9648Q92343980-51FC1919-A6E2-44EE-9C55-DCC0156E0096Q92664070-CD4C8440-C907-4F30-867F-9787CCB07BEB
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sylvie Claeysen
@ast
Sylvie Claeysen
@en
Sylvie Claeysen
@es
Sylvie Claeysen
@nl
type
label
Sylvie Claeysen
@ast
Sylvie Claeysen
@en
Sylvie Claeysen
@es
Sylvie Claeysen
@nl
prefLabel
Sylvie Claeysen
@ast
Sylvie Claeysen
@en
Sylvie Claeysen
@es
Sylvie Claeysen
@nl
P106
P21
P31
P496
0000-0002-0576-5518